WO2000010551A3 - Methods of using and compositions comprising dopamine reuptake inhibitors - Google Patents

Methods of using and compositions comprising dopamine reuptake inhibitors Download PDF

Info

Publication number
WO2000010551A3
WO2000010551A3 PCT/US1999/019167 US9919167W WO0010551A3 WO 2000010551 A3 WO2000010551 A3 WO 2000010551A3 US 9919167 W US9919167 W US 9919167W WO 0010551 A3 WO0010551 A3 WO 0010551A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
dopamine reuptake
pharmacologically active
methods
additional pharmacologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019167
Other languages
French (fr)
Other versions
WO2000010551A2 (en
Inventor
Thomas P Jerussi
Chrisantha H Senanayake
Qun K Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ510193A priority Critical patent/NZ510193A/en
Priority to IL14153199A priority patent/IL141531A0/en
Priority to EP99945137A priority patent/EP1107746B1/en
Priority to CA2341441A priority patent/CA2341441C/en
Priority to KR1020017002288A priority patent/KR20010085553A/en
Priority to AU57817/99A priority patent/AU772303B2/en
Priority to AT99945137T priority patent/ATE279184T1/en
Priority to DE69921157T priority patent/DE69921157T2/en
Priority to JP2000565873A priority patent/JP2002523366A/en
Priority to BR9913325-3A priority patent/BR9913325A/en
Priority to CNB998124664A priority patent/CN100415222C/en
Priority to KR1020067012844A priority patent/KR100887008B1/en
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to HK06108671.3A priority patent/HK1088238B/en
Publication of WO2000010551A2 publication Critical patent/WO2000010551A2/en
Publication of WO2000010551A3 publication Critical patent/WO2000010551A3/en
Priority to IL141531A priority patent/IL141531A/en
Priority to NO20010943A priority patent/NO20010943L/en
Anticipated expiration legal-status Critical
Priority to AU2004200875A priority patent/AU2004200875B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Information Transfer Systems (AREA)

Abstract

Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites like desmethylsibutramine and didesmethylsibutramine and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3, antagonists.
PCT/US1999/019167 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors Ceased WO2000010551A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CNB998124664A CN100415222C (en) 1998-08-24 1999-08-23 Methods of using dopamine reuptake inhibitors and compositions comprising them
EP99945137A EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
CA2341441A CA2341441C (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
KR1020017002288A KR20010085553A (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
AU57817/99A AU772303B2 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
AT99945137T ATE279184T1 (en) 1998-08-24 1999-08-23 METHODS OF USE AND COMPOSITIONS CONTAINING A DOPAMINE REUPPOST INHIBITOR
DE69921157T DE69921157T2 (en) 1998-08-24 1999-08-23 USE METHODS AND COMPOSITIONS CONTAINING A DOPAMINE RECEPTION INHIBITOR
JP2000565873A JP2002523366A (en) 1998-08-24 1999-08-23 Compositions containing dopamine reuptake inhibitors and methods of using the same
BR9913325-3A BR9913325A (en) 1998-08-24 1999-08-23 Method of treatment or prevention of a disorder or condition improved (a) by inhibiting neuronal monoamine uptake, erectile dysfunction, affective disorder, weight gain or obesity, brain function disorders, pain , obsessive-compulsive disorder, substance abuse, nicotine addiction, smoking cessation, weight gain associated with smoking cessation, a chronic disorder selected from the group consisting of narcolepsy, chronic fatigue syndrome, disorder seasonal affective, fibromyalgia, and premenstrual syndrome, anxiety, eating disorders, migraines, incontinence, pharmaceutical composition, and lactose-free pharmaceutical composition
NZ510193A NZ510193A (en) 1998-08-24 1999-08-23 Use of a sibutramine metabolite to treat or prevent attention deficit disorder and attention deficit disorder with hyperactivity
IL14153199A IL141531A0 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
KR1020067012844A KR100887008B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
HK06108671.3A HK1088238B (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
IL141531A IL141531A (en) 1998-08-24 2001-02-20 Use of a sibutramine metabolite for the manufacture of a medicament for treating attention deficit disorder (add)
NO20010943A NO20010943L (en) 1998-08-24 2001-02-23 Process for use and compositions including dopamine reuptake inhibitors
AU2004200875A AU2004200875B2 (en) 1998-08-24 2004-03-03 Methods of using and compositions comprising dopamine reuptake inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9766598P 1998-08-24 1998-08-24
US9930698P 1998-09-02 1998-09-02
US09/372,158 US6331571B1 (en) 1998-08-24 1999-08-11 Methods of treating and preventing attention deficit disorders
US60/099,306 1999-08-11
US09/372,158 1999-08-11
US60/097,665 1999-08-11

Publications (2)

Publication Number Publication Date
WO2000010551A2 WO2000010551A2 (en) 2000-03-02
WO2000010551A3 true WO2000010551A3 (en) 2000-09-21

Family

ID=27378425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019167 Ceased WO2000010551A2 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Country Status (20)

Country Link
US (3) US6331571B1 (en)
EP (2) EP1107746B1 (en)
JP (1) JP2002523366A (en)
KR (3) KR20010085553A (en)
CN (1) CN100415222C (en)
AT (1) ATE279184T1 (en)
AU (2) AU772303B2 (en)
CA (1) CA2341441C (en)
CZ (1) CZ2001677A3 (en)
DE (1) DE69921157T2 (en)
DK (1) DK1107746T3 (en)
ES (1) ES2226435T3 (en)
HU (1) HUP0103408A3 (en)
ID (1) ID28638A (en)
IL (2) IL141531A0 (en)
NO (1) NO20010943L (en)
NZ (1) NZ510193A (en)
PL (1) PL200264B1 (en)
PT (1) PT1107746E (en)
WO (1) WO2000010551A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
MXPA01009404A (en) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Method of treating eating disorders.
DE60022692T2 (en) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S, S) reboxetine for the treatment of migraine headache
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) * 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
ATE409475T1 (en) * 2001-02-20 2008-10-15 Dinan Timothy Gerard TREATING FIBROMYALGIA WITH PINDOLOL
DE10142666A1 (en) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
CA2484482C (en) * 2002-05-30 2011-07-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
AU2003268361A1 (en) * 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005072715A1 (en) * 2004-01-29 2005-08-11 Sepracor Inc. Use of (s)-didesmethylsibutraminefor treating, preventing and managing a sleep disorder
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
DK1742624T3 (en) * 2004-02-18 2010-03-08 Sepracor Inc Dopamine agonist combination therapy with sedatives to improve sleep quality
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
KR100618176B1 (en) * 2004-12-02 2006-09-01 휴먼팜 주식회사 Sibutramine stannate, preparation method thereof and pharmaceutical composition comprising the same
EP1828096A2 (en) * 2004-12-22 2007-09-05 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Enantioselective synthesis of a sterically hindered amine
KR20060080818A (en) * 2005-01-06 2006-07-11 씨제이 주식회사 Sulfonates of sibutramine
KR20060080817A (en) * 2005-01-06 2006-07-11 씨제이 주식회사 Dicarboxylate of Sibutramine
JP2008526836A (en) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション Sibutramine inorganic acid salt
KR20060093564A (en) * 2005-02-22 2006-08-25 종근당바이오 주식회사 Anhydrous sibutramine malate and a process for producing the same
KR100632470B1 (en) * 2005-02-25 2006-10-12 민연식 Crystalline Sibutramine Kamsylate Salt And Method For Preparing The Same
PL385455A1 (en) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Oral disintegrating pharmaceutical tablet of olanzapine preparations
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS
ATE490963T1 (en) * 2006-03-10 2010-12-15 Univ New York State Res Found TROPAN PRODRUGS WITH ACTIVITY ON THE CNS
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
CN101674728A (en) * 2007-02-12 2010-03-17 Dmi生物科学公司 Reduce side effects of tramadol
US20110244059A1 (en) * 2008-08-20 2011-10-06 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
ES2705027T3 (en) 2010-08-19 2019-03-21 Buck Institute For Age Res Methods of treatment of mild cognitive impairment (MCI) and related disorders
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113908295B (en) * 2021-11-12 2023-07-21 郑州大学第一附属医院 A kind of alprazolam inclusion compound and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3212682A1 (en) * 1981-04-06 1982-10-21 The Boots Co. Ltd., Nottingham SUBSTITUTED CYCLOBUTANE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS
WO1988006444A1 (en) * 1987-02-28 1988-09-07 The Boots Company Plc Arylcyclobutyl derivatives for treatment of parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
WO1995021615A1 (en) * 1994-02-11 1995-08-17 Knoll Ag Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
EP0781561A1 (en) * 1994-09-19 1997-07-02 Fujisawa Pharmaceutical Co., Ltd. Novel medicinal use of 5ht 3? antagonist
WO1998013034A1 (en) * 1996-09-25 1998-04-02 Knoll Aktiengesellschaft Use of sibutramine analogues to lower lipid levels
WO1999033450A2 (en) * 1997-12-24 1999-07-08 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (en) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt PHARMACEUTICAL PREPARATIONS
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
JPS5940638A (en) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd Silver halide photographic emulsion for direct positive
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0554172B1 (en) 1992-01-28 1998-04-29 Fujitsu Limited Color surface discharge type plasma display device
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
CA2138998A1 (en) 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (en) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidines
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3212682A1 (en) * 1981-04-06 1982-10-21 The Boots Co. Ltd., Nottingham SUBSTITUTED CYCLOBUTANE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS
WO1988006444A1 (en) * 1987-02-28 1988-09-07 The Boots Company Plc Arylcyclobutyl derivatives for treatment of parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
WO1995021615A1 (en) * 1994-02-11 1995-08-17 Knoll Ag Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
EP0781561A1 (en) * 1994-09-19 1997-07-02 Fujisawa Pharmaceutical Co., Ltd. Novel medicinal use of 5ht 3? antagonist
WO1998013034A1 (en) * 1996-09-25 1998-04-02 Knoll Aktiengesellschaft Use of sibutramine analogues to lower lipid levels
WO1999033450A2 (en) * 1997-12-24 1999-07-08 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEETHAM, S. C. ET AL: "[3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments", NEUROPHARMACOLOGY (1993), 32(8), 737-43, XP000905163 *
GRAY, A. M.; SPENCER, P. S. J.; SEWELL, R. D. E.: "The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds", BR. J. PHARMACOL., vol. 124, no. 4, 1998, pages 669 - 674, XP000909217 *
HEAL, D. J. ET AL: "A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents", BR. J. PHARMACOL. (1998), 125(2), 301-308, XP000905054 *
JEFFERY, JAMES E. ET AL: "Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites", J. CHEM. SOC., PERKIN TRANS. 1 (1996), (21), 2583-2589, XP002137121 *
LUSCOMBE G P ET AL: "THE CONTRIBUTION OF METABOLITES TO THE RAPID AND POTENT DOWN-REGULATION OF RAT CORTICAL BETA-ADRENOCEPTORS BY THE PUTATIVE ANTIDEPRESSANT SIBUTRAMINE HYDROCHLORIDE", NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, vol. 28, no. 2, 1 February 1989 (1989-02-01), pages 129 - 134, XP000613753, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
US20020188029A1 (en) 2002-12-12
AU772303B2 (en) 2004-04-22
AU5781799A (en) 2000-03-14
DE69921157T2 (en) 2006-02-02
EP1107746A2 (en) 2001-06-20
HUP0103408A2 (en) 2002-05-29
AU2004200875A1 (en) 2004-04-01
NO20010943D0 (en) 2001-02-23
CA2341441A1 (en) 2000-03-02
US6538034B2 (en) 2003-03-25
WO2000010551A2 (en) 2000-03-02
US20030195261A1 (en) 2003-10-16
ATE279184T1 (en) 2004-10-15
AU2004200875B2 (en) 2006-10-26
KR20080011354A (en) 2008-02-01
ID28638A (en) 2001-06-21
DE69921157D1 (en) 2004-11-18
IL141531A (en) 2010-05-31
EP1107746B1 (en) 2004-10-13
US6331571B1 (en) 2001-12-18
HUP0103408A3 (en) 2002-10-28
NZ510193A (en) 2003-09-26
CN100415222C (en) 2008-09-03
PL346843A1 (en) 2002-02-25
KR100887008B1 (en) 2009-03-04
IL141531A0 (en) 2002-05-23
PL200264B1 (en) 2008-12-31
EP1475086A2 (en) 2004-11-10
KR20010085553A (en) 2001-09-07
KR20060081725A (en) 2006-07-13
HK1088238A1 (en) 2006-11-03
NO20010943L (en) 2001-04-23
CZ2001677A3 (en) 2002-02-13
EP1475086A3 (en) 2006-12-13
ES2226435T3 (en) 2005-03-16
PT1107746E (en) 2005-03-31
DK1107746T3 (en) 2005-02-14
US7071234B2 (en) 2006-07-04
CA2341441C (en) 2011-07-19
CN1735407A (en) 2006-02-15
JP2002523366A (en) 2002-07-30

Similar Documents

Publication Publication Date Title
WO2000010551A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
WO2004073632A3 (en) Rapid absorption selective 5-ht agonist formulations
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
JP2010535801A5 (en)
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
KR950704311A (en) QUINUCLIDINE DERIVATIVE AS SUBSTANCE P ANTAGONIST
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
WO2005072740A3 (en) Anorectic compounds
MXPA02001306A (en) Pharmaceutical compositions for the treatment of cns and other discorders.
WO2005037832A3 (en) Azabicycyclic compounds for relieving pain and treating central nervous system disorders
CA2360313A1 (en) Glucocorticoid receptor modulators
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
WO2002018348A3 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
CA2360308A1 (en) Glucocorticoid receptor modulators
WO2004041272A3 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
CN104640449A (en) Pramipexole transdermal delivery for severe headaches
SK287180B6 (en) Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments
WO2004096118A3 (en) Composition for improving cognition and memory
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
WO2005062894A3 (en) Co-administration of dopamine-receptor binding compounds
WO2004080393A3 (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
WO2005094218A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812466.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141531

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2341441

Country of ref document: CA

Ref document number: 2341441

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-677

Country of ref document: CZ

Ref document number: 2001/01498

Country of ref document: ZA

Ref document number: 200101498

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001955

Country of ref document: MX

Ref document number: 1020017002288

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 510193

Country of ref document: NZ

Ref document number: 57817/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/405/CHE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1999945137

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017002288

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-677

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 57817/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999945137

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017002288

Country of ref document: KR